Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) EBIT: 2021-2025

Historic EBIT for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.

  • ProQR Therapeutics N.V's EBIT fell 44.50% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 79.87%. This contributed to the annual value of -$32.6 million for FY2024, which is 5.51% up from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported EBIT of -$12.9 million as of Q3 2025, which was up 6.53% from -$13.8 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's EBIT ranged from a high of -$3.1 million in Q2 2024 and a low of -$23.4 million during Q3 2022.
  • Its 3-year average for EBIT is -$8.9 million, with a median of -$8.9 million in 2024.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's EBIT skyrocketed by 74.62% in 2023, and later crashed by 342.01% in 2025.
  • Over the past 5 years, ProQR Therapeutics N.V's EBIT (Quarterly) stood at -$20.8 million in 2021, then skyrocketed by 34.89% to -$13.6 million in 2022, then surged by 56.56% to -$5.9 million in 2023, then crashed by 68.70% to -$9.9 million in 2024, then crashed by 44.50% to -$12.9 million in 2025.
  • Its last three reported values are -$12.9 million in Q3 2025, -$13.8 million for Q2 2025, and -$10.6 million during Q1 2025.